MARKET

VERV

VERV

Verve Therapeutics, Inc.
NASDAQ
4.230
-0.250
-5.58%
After Hours: 4.200 -0.03 -0.71% 19:47 05/09 EDT
OPEN
4.510
PREV CLOSE
4.480
HIGH
4.590
LOW
4.170
VOLUME
2.11M
TURNOVER
--
52 WEEK HIGH
9.31
52 WEEK LOW
2.865
MARKET CAP
377.08M
P/E (TTM)
-1.8035
1D
5D
1M
3M
1Y
5Y
1D
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 3d ago
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
Seeking Alpha · 3d ago
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
Benzinga · 4d ago
Weekly Report: what happened at VERV last week (0428-0502)?
Weekly Report · 6d ago
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
The Motley Fool · 04/29 11:53
Weekly Report: what happened at VERV last week (0421-0425)?
Weekly Report · 04/28 09:30
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Benzinga · 04/21 14:36
Weekly Report: what happened at VERV last week (0414-0418)?
Weekly Report · 04/21 09:30
More
About VERV
More
Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Recently
Symbol
Price
%Change
    FXF
  • 106.83
  • +0.03%

Webull offers Verve Therapeutics Inc stock information, including NASDAQ: VERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERV stock methods without spending real money on the virtual paper trading platform.